The impacts of ribociclib on the post-treatment Tp-e interval and Tp-e/QTc ratio in breast cancer patients.
1/5 보강
[PURPOSE] The study aimed to assess the impacts of ribociclib on the post-treatment Tp-e interval and Tp-e/QTc ratio in breast cancer patients.
- p-value p < 0.05
APA
Çiriş Ş, Seyyar M, et al. (2026). The impacts of ribociclib on the post-treatment Tp-e interval and Tp-e/QTc ratio in breast cancer patients.. Advances in medical sciences, 71(1), 83-87. https://doi.org/10.1016/j.advms.2026.03.002
MLA
Çiriş Ş, et al.. "The impacts of ribociclib on the post-treatment Tp-e interval and Tp-e/QTc ratio in breast cancer patients.." Advances in medical sciences, vol. 71, no. 1, 2026, pp. 83-87.
PMID
41812826 ↗
Abstract 한글 요약
[PURPOSE] The study aimed to assess the impacts of ribociclib on the post-treatment Tp-e interval and Tp-e/QTc ratio in breast cancer patients.
[MATERIALS/METHODS] A retrospective study was carried out with 40 breast cancer patients between October 2023 and February 2024 to reveal the impacts of ribociclib therapy (either alone or in combination with letrozole) on the post-treatment Tp-e interval and Tp-e/QTc ratio. ECGs obtained before the start of the treatment and on the 21st day of the 3rd course were used in the evaluation.
[RESULTS] Patients' pre-treatment heart rate, WBC, AST, QRS (ms), Tp-e/QT, and Tp-e/JT values decreased after the treatment (p < 0.05). Patients' pre-treatment QT, JT (ms), JTc(ms), Tp-e(ms), Tp-e/Qtc, and Tp-e/JTc values increased after the treatment (p < 0.05). Patients' pre- and post-treatment ionized Ca/(Tpe/JTc) values showed statistically significant difference (p < 0.01). The pre-treatment ionized Ca/(Tpe/JTc) values of patients decreased significantly after the treatment. The ionized Ca/(Tpe/QTc) values of patients differed statistically significantly before and after the treatment (p < 0.01). Patients' pre-treatment ionized Ca/(Tpe/QTc) values decreased significantly after the treatment.
[CONCLUSION] The potential arrhythmogenic effects of ribociclib suggest that serum calcium (Ca), ionized calcium, QT, QTc, Tp-e interval, and Tp-e/QTc ratio may be monitored throughout the treatment period.
[MATERIALS/METHODS] A retrospective study was carried out with 40 breast cancer patients between October 2023 and February 2024 to reveal the impacts of ribociclib therapy (either alone or in combination with letrozole) on the post-treatment Tp-e interval and Tp-e/QTc ratio. ECGs obtained before the start of the treatment and on the 21st day of the 3rd course were used in the evaluation.
[RESULTS] Patients' pre-treatment heart rate, WBC, AST, QRS (ms), Tp-e/QT, and Tp-e/JT values decreased after the treatment (p < 0.05). Patients' pre-treatment QT, JT (ms), JTc(ms), Tp-e(ms), Tp-e/Qtc, and Tp-e/JTc values increased after the treatment (p < 0.05). Patients' pre- and post-treatment ionized Ca/(Tpe/JTc) values showed statistically significant difference (p < 0.01). The pre-treatment ionized Ca/(Tpe/JTc) values of patients decreased significantly after the treatment. The ionized Ca/(Tpe/QTc) values of patients differed statistically significantly before and after the treatment (p < 0.01). Patients' pre-treatment ionized Ca/(Tpe/QTc) values decreased significantly after the treatment.
[CONCLUSION] The potential arrhythmogenic effects of ribociclib suggest that serum calcium (Ca), ionized calcium, QT, QTc, Tp-e interval, and Tp-e/QTc ratio may be monitored throughout the treatment period.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Early local immune activation following intra-operative radiotherapy in human breast tissue.
- Overall survival and prognostic factors in young women with breast cancer: a retrospective cohort study from Southern Thailand.
- Age at First Pregnancy, Adult Weight Gain and Postmenopausal Breast Cancer Risk: The PROCAS Study (United Kingdom).
- Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates.
- Structural determinants of glycosaminoglycan oligosaccharides as LL-37 inhibitors in breast cancer.
- Artificial intelligence and breast cancer screening in Serbia: a dual-perspective qualitative study among radiologists and screening-aged women.